olcegepant
Small moleculeexperimental
Olcegepant is a calcitonin gene-related peptide receptor antagonist being studied as a potential treatment for migraines. — Wikipedia
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 1998 (NCT02198352)
Timeline
Indications
Mechanism of action
CALCRL antagonist
Chemistry & pharmacology
Loading structure…
SMILES
NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(N2Cc3ccccc3NC2=O)CC1)C(=O)N1CCN(c2ccncc2)CC1- Mol. weight
- 869.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOlcegepant ↗
- ChEMBLCHEMBL207197 ↗
Also known as
- 1-(n(2)-(3,4-dibromo-n-((4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl)carbonyl)tyrosyl)lysyl)-4-(4-pyridinyl)piperazine
- bibn4096
- bibn 4096
- bibn 4096
- bibn 4096
- bibn-4096
- bibn 4096 bs
- bibn 4096 bs
- bibn-4096bs
- bibn-4096bs
- olcegepant
- olcegepant
- olcegepant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02199860 | Phase 1 | May 1, 2003 | Boehringer Ingelheim |
| NCT02194322 | Phase 1 | Nov 1, 2001 | Boehringer Ingelheim |
| NCT02194777 | Phase 1 | Jun 1, 2001 | Boehringer Ingelheim |
| NCT02194335 | Phase 1 | Oct 1, 2000 | Boehringer Ingelheim |
| NCT02194348 | Phase 1 | Feb 1, 2000 | Boehringer Ingelheim |
| NCT02198326 | Phase 1 | Jul 1, 1999 | Boehringer Ingelheim |
| NCT02198339 | Phase 2 | Feb 1, 1999 | Boehringer Ingelheim |
| NCT02198352 | Phase 1 | Jun 1, 1998 | Boehringer Ingelheim |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 8 | 8 | 2 | 1998 |
1 organizations
Page 1 / 1